Article
Cost-effective shallow genome-wide sequencing for profiling plasma cfDNA signatures to enhance lung cancer detection.
Future oncology (London, England) - 1 May 2025
Nguyen Van Thien Chi, Vo Dac Ho, Tran Thi Trang, Tran Thanh Truong, Nguyen Thi Hue Hanh, Vo Truong Dang Huy, Van Thi Tuong Vi, Vu Thi Luyen, Lam Minh Quang, Nguyen Giang Thi Huong, Tran Trung Hieu, Pham Ngoc Tan, Trac Quang Thinh, Nguyen Trong Hieu, Phan Thi Van, Dao Thi Huyen, Nguyen Huu Tam Phuc, Nguyen Luu Hong Dang, Nguyen Duy Sinh, Tang Hung Sang, Giang Hoa, Phan Minh Duy, Nguyen Hoai-Nghia, Tran Le Son
Abstract excerpt
BACKGROUND: Lung cancer (LC) screening via low-dose computed tomography (LDCT) faces challenges including high false-positive rates and low patient compliance. Circulating tumor DNA (ctDNA)-based tests offer a minimally invasive alternative but are limited by high costs and low sensitivity, particularly in early-stage detection. This study introduces a cost-effective, shallow genome-wide sequencing approach for...
Topics
Join the communities discussing this publication.